Review Article
Impact of S100A4 Expression on Clinicopathological Characteristics and Prognosis in Pancreatic Cancer: A Meta-Analysis
Table 1
Characteristics of the included studies (P: S100A4-positive; N: S100A4-negative; NA: not available).
| | Author | Year | Country | Number of patients | Duration of follow-up | Cutoff scores (positive/negative) | N category (N0/N1) | Distant metastasis (M0/M1) | Histology (well, mod/Por) | 3-year OS rate |
| |
Oida et al. [26] | 2006 | Japan | 72 | NA | >NA (40/32) | P (5/35)
N (7/25) | P (24/16)
N (20/12) | P (37/3)
N (27/5) | P 7.5% (3/40)
N 31.3% (10/32) | |
Ai et al. [27] | 2008 | China | 62 | NA | Score ⩾ 2 (38/24) | P (5/33)
N (8/16) | P (23/15)
N (16/8) | P (21/17)
N (11/13) | P 2.1% (1/38)
N 20.8% (5/24) | |
Tsukamoto et al. [19] | 2013 | Japan | 83 | NA | >5% (48/35) | P (12/36)
N (12/23) | NA | P (38/10)
N (32/3) | P 10.4% (5/48)
N 17.1% (6/35) | |
Lee et al. [28] | 2014 | Korea | 67 | Median 16.9 months | Score ⩾ 2 (36/31) | NA | NA | NA | P 11.1% (4/36)
N 35.5% (11/31) | |
Jia [29] | 2011 | China | 63 | 4–36 months | Score ⩾ 2 (47/16) | P (14/33)
N (12/4) | P (31/16)
N (16/10) | P (32/15)
N (15/1) | P 0% (0/47)
N 37.5% (6/16) | |
Liu [30] | 2011 | China | 82 | NA | Score ⩾ 2 (57/25) | P (16/41)
N (16/9) | NA | P (37/20)
N (24/1) | NA | |
Liu [31] | 2004 | China | 45 | NA | >20% (21/24) | P (3/18)
N (12/12) | NA | P (10/11)
N (20/4) | NA |
|
|
